BioCentury | May 3, 2010
Clinical News

7TM preclinical data

...In a mouse model of chemotherapy-induced gastrointestinal disease, TM30339 improved survival and mucositis outcome post X-ray...
...is in Phase I/II testing to treat obesity. 7TM Pharma A/S , Horsholm, Denmark Product: TM30339...
BioCentury | Jan 16, 2009
Financial News

7TM raises $13.4 million

...treat obesity: obinepitide , a synthetic analog of human hormones PYY3-36 and pancreatic polypeptide; and TM30339...
BioCentury | Sep 8, 2008
Clinical News

TM30339: Phase I/II started

...7TM Pharma began a double-blind, placebo-controlled, U.S. Phase I/Ila trial to evaluate TM30339 in patients with...
...a BMI of 30-40 for 28 days. *** 7TM Pharma A/S , Horsholm, Denmark Product: TM30339...
BioCentury | Mar 3, 2008
Clinical News

TM30339: Phase Ia data

...In a French Phase Ia trial in volunteers, TM30339 was safe and well tolerated. 7TM also...
...7TM also said the compound had good pharmacokinetics. 7TM Pharma A/S , Horsholm, Denmark Product: TM30339...
BioCentury | Mar 3, 2008
Clinical News

TM30339: Phase Ib data

...obese volunteers, TM30339 was safe and well tolerated. 7TM Pharma A/S , Horsholm, Denmark Product: TM30339...
BioCentury | Jun 9, 2007
Financial News

7TM raises $22.2 million

...led by SR One. 7TM's neuropeptide Y (NPY) receptor agonists obinepitide ( TM30338 ) and TM30339...
BioCentury | May 29, 2006
Strategy

Going for aggregation

...is enough to get its two neuropeptide Y (NPY) receptor agonists for obesity, TM30338 and TM30339...
...end of Phase II and Phase I/II, respectively. TM30338 recently completed Phase I/II trials and TM30339...
...late preclinical development. A Phase II trial of TM30338 and a Phase I/II trial of TM30339...
Items per page:
1 - 7 of 7